Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Vyant Bio, Inc. VYNT NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
19/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Vyant Bio, Inc. (VYNT) is a Biotechnology company in the Healthcare sector, currently trading at $0.19. It has a SharesGrow Score of 18/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $666,000, -32.6%/yr average growth. Net income is $23M (loss), growing at -129.2%/yr. Net profit margin is -3406.9% (negative). Gross margin is -51.4% (-100.7 pp trend).

Balance sheet: total debt is $2M against $10M equity (Debt-to-Equity (D/E) ratio 0.22, conservative). Current ratio is 3.14 (strong liquidity). Debt-to-assets is 14.4%. Total assets: $15M.

Analyst outlook: 0 / 1 analysts rate VYNT as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 0/100 (Fail), Future 20/100 (Fail), Income 10/100 (Fail).

VYNT SharesGrow Score Overview

28/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VYNT

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
VYNT: -32.6%/yr revenue is, -129.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet VYNT: Debt-to-Equity (D/E) ratio 0.22 (conservative), Current ratio is 3.14 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
✗
FUTURE Fail
20/100
Analyst outlook: 0 / 1 analysts rate VYNT as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
VYNT: Net profit margin is -3406.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.141-1.58
Volume19.12K
Avg Volume (30D)17.86K
Beta (1Y)0.56
Share Statistics
EPS (TTM)-3.87
Shares Outstanding$5.87M
IPO Date2021-04-01
Employees4
CEOAndrew D.C. LaFrence CPA
Financial Highlights & Ratios
Revenue (TTM)$666K
Gross Profit$-342K
EBITDA$-15.07M
Net Income$-22.69M
Operating Income$-15.91M
Total Cash$10.04M
Total Debt$2.2M
Net Debt$-7.85M
Total Assets$15.21M
Price / Earnings (P/E)-0.1
Analyst Forecast
Rating ConsensusHold
Analysts Covering1
Buy 0% Hold 100% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS92942V2088

Price Chart

Track all markets on TradingView
VYNT
Vyant Bio, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.14 52WK RANGE 1.58

People Also View

FBRX
FBRX
Forte Biosciences, Inc.
$32.42
+5.95%
 DMAC
DMAC
DiaMedica Therapeutics Inc.
$6.54
+3.81%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 SRZN
SRZN
Surrozen, Inc.
$31.07
+4.05%
 MOLN
MOLN
Molecular Partners AG
$4.14
-1.66%
 ALGS
ALGS
Aligos Therapeutics, Inc.
$8.55
-1.04%
 NTRB
NTRB
Nutriband Inc.
$4.06
+2.01%
 SABS
SABS
SAB Biotherapeutics, Inc.
$3.86
-1.03%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message